XLCART001
Cell therapyexperimental
Clinical trial activity
4 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 23, 2017 (NCT03291444)
Timeline
Indications
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05225363 | Phase 1 | May 5, 2022 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT03598179 | Phase 2 | Jun 1, 2018 | Nanjing Medical University |
| NCT03423992 | Phase 1 | Feb 15, 2018 | Capital Medical University, Hebei Senlang Biotechnology Inc., Ltd. |
| NCT03291444 | Phase 1 | Sep 23, 2017 | Shenzhen Geno-Immune Medical Institute, Southern Medical University, Sun Yat-Sen University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Capital Medical University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| City of Hope National Medical Center | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Hebei Senlang Biotechnology Inc., Ltd. | For profit | 1 | 0 | 1 | 2018 |
| Nanjing Medical University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2022 |
| Shenzhen Geno-Immune Medical Institute | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Southern Medical University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2017 |
8 organizations
Page 1 / 1